Coya Therapeutics appoints former US Secretary of Commerce Wilbur L. Ross to board of directors

Coya Therapeutics, Inc.

Board expanded to seven directors; Ross appointed Class I director effective Dec 19, 2023, term until 2026 annual meeting.
Ross granted options for 10,000 shares at closing price on Jan 2, 2024, vesting on one-year anniversary of appointment.
Coya will leverage Ross's 55+ years of investment banking, private equity, and government experience for strategic partnerships and capital markets.
Ross served as 39th US Secretary of Commerce (2017-2021) and is former Chairman & CSO of WL Ross & Co.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Wilbur L. Ross

Director

COYA · Coya Therapeutics, Inc.

Effective: 2023-12-19
Filed: December 20, 2023, 6:59 PM ET

On December 19, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to seven directors from six, and appointed Wilbur L. Ross (“Secretary Ross”) as a Class I director to fill the newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wilbur L. Ross was appointed as Director at Coya Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 19, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to seven directors from six, and appointed Wilbur L. Ross (“Secretary Ross”) as a Class I director to fill the newly created vacancy.

View on SEC.gov

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-299370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.